|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients with Autoimmune Hemolytic Anemia Have Failed ≥ 3 Lines of Therapy
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines of therapy.
100 项与 Hangzhou Xiniao Biotechnology Co., Ltd. 相关的临床结果
0 项与 Hangzhou Xiniao Biotechnology Co., Ltd. 相关的专利(医药)
100 项与 Hangzhou Xiniao Biotechnology Co., Ltd. 相关的药物交易
100 项与 Hangzhou Xiniao Biotechnology Co., Ltd. 相关的转化医学